We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bioventix PLC | AQSE:BVXP.GB | Aquis Stock Exchange | Ordinary Share | GB00B4QVDF07 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4,525.00 | 4,250.00 | 4,800.00 | 4,525.00 | 4,450.50 | 4,525.00 | 5 | 16:29:38 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMBVXP Bioventix plc ("Bioventix" or the "Company") Director/PDMR Shareholding Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, was notified on 18 November 2016 of the following transactions in its ordinary shares of 5 pence each ("Ordinary Shares"): Director Position Ordinary Sale price Ordinary Percentage Shares per Shares held of issued sold Ordinary subsequently share Share capital held subsequently Ian Nicholson and Non-Executive 4,000 1300p 23,000 0.45% Persons Closely Chairman Associated Peter Harrison and CEO 100,000 1300p 508,176 9.96% Persons Closely Associated Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them Details of the person discharging managerial responsibilities / person closely associated a) Names Ian Nicholson (Non-Executive Chairman) Catherine Nicholson (PCA of Ian Nicholson) Peter Harrison (CEO) Abigail Harrison (PCA of Peter Harrison) Reason for the Notification a) Position/status See 1(a) above, all are PDMR's or PCA's of PDMR's b) Initial notification/ Initial notification Amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Bioventix plc b) LEI n/a Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the Ordinary shares of 5 pence ("Ordinary Financial instrument, Shares") type of instrument Identification code GB00B4QVDF07 b) Nature of the In each case, sale of Ordinary Shares transaction c) Price(s) and volume(s) Ian Nicholson: Price(s) Volume(s) 1300 pence 2,000 Catherine Nicholson: Price(s) Volume(s) 1300 pence 2,000 Peter Harrison: Price(s) Volume(s) 1300 pence 98,000 Abigail Harrison: Price(s) Volume(s) 1300 pence 2,000 d) Aggregated information: Sale of 2,000 Ordinary Shares at a price of 1300 pence per Ordinary Share Sale of 2,000 Ordinary Shares at a price of 1300 pence per Ordinary Share Sale of 98,000 Ordinary Shares at a price of 1300 pence per Ordinary Share Sale of 2,000 Ordinary Shares at a price of 1300 pence per Ordinary Share e) Date of the transaction 18 November 2016 f) Place of the London Stock Exchange, AIM Market (XLON) transaction For further information please contact: Bioventix plc Tel: 01252 728 001 Peter Harrison Chief Executive Officer finnCap Ltd Tel: 020 7220 0500 Geoff Nash/Simon Hicks Corporate Finance Stephen Norcross Corporate Broking About Bioventix plc: Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP. END
(END) Dow Jones Newswires
November 18, 2016 13:01 ET (18:01 GMT)
1 Year Bioventix Chart |
1 Month Bioventix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions